指南与共识膀胱癌与上尿路尿路上皮癌

1973年与2004/2016年世界卫生组织分级系统在非肌层浸润性膀胱癌中的预后效能与可重复性:欧洲泌尿外科学会非肌层浸润性膀胱癌指南专家组系统综述

Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review.
指南 / 共识 · Eur Urol · 2017-04-28

本系统综述纳入20项预后研究及3项可重复性研究,比较1973年与2004/2016年世界卫生组织(WHO)分级系统在非肌层浸润性膀胱癌中的预后效能与可重复性。两种分级中肿瘤级别升高均与更高的疾病进展和复发率相关;2004/2016系统可重复性略优于1973系统,但多数研究偏倚风险为中至高度,作者认为现有分级系统欠佳,无法确认2004/2016系统在预测复发和进展方面优于1973系统。

要点

  • 两种分级系统中肿瘤级别升高均与更高的疾病进展率和复发率相关。
  • 2004/2016系统的可重复性略优于1973系统,但差异有限。
  • 多数纳入研究偏倚风险为中至高度,现有分级系统欠佳。

核心结论

  • 现有非肌层浸润性膀胱癌分级系统欠佳,1973系统识别出更多侵袭性肿瘤,2004/2016系统观察者内和观察者间变异略小。
  • 作者无法确认2004/2016分级系统在预测复发和进展方面优于1973分级系统。
  • 两系统均可预测进展和复发,但病理医师报告存在差异,作者提出了进一步改进的建议。

研究设计与样本

  • 欧洲泌尿外科学会(EAU)非肌层浸润性膀胱癌指南专家组系统综述,检索Medline、Embase和Cochrane Library。
  • 共识别3593篇文章,20篇纳入预后评价,3篇符合可重复性评价条件。
  • 采用QUIPS工具进行偏倚风险批判性评估。

主要发现

  • 两种分级系统中肿瘤级别升高均与更高的疾病进展率和复发率相关。
  • 1级患者的进展率与低级别患者相似,3级患者的进展率高于高级别患者。
  • 生存数据有限。
  • 2004/2016系统的可重复性略优于1973系统,两项关于重复性的研究结果相互矛盾。
  • 多数研究偏倚风险为中至高度。

关键数值与推荐

  • 预后主要结局为进展为肌层浸润性疾病或转移性疾病,次要结局为疾病复发、总生存和癌症特异性生存。
  • 可重复性主要结局为病理医师间观察者间变异,次要结局为同一病理医师的观察者内变异(重复性)。

临床怎么用

  • 欧洲泌尿外科学会非肌层浸润性膀胱癌指南建议同时使用1973年和2004/2016年世界卫生组织(WHO)分级。
  • 原文未据此给出其他推荐。

局限性

  • 多数研究偏倚风险为中至高度。
  • 生存数据有限。
  • 两项关于重复性的研究结果相互矛盾。
  • 作者无法确认2004/2016分级系统在预测复发和进展方面优于1973分级系统。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Tumour grade is an important prognostic indicator in non-muscle-invasive bladder cancer (NMIBC). Histopathological classifications are limited by interobserver variability (reproducibility), which may have prognostic implications. European Association of Urology NMIBC guidelines suggest concurrent use of both 1973 and 2004/2016 World Health Organization (WHO) classifications. OBJECTIVE: To compare the prognostic performance and reproducibility of the 1973 and 2004/2016 WHO grading systems for NMIBC. EVIDENCE ACQUISITION: A systematic literature search was undertaken incorporating Medline, Embase, and the Cochrane Library. Studies were critically appraised for risk of bias (QUIPS). For prognosis, the primary outcome was progression to muscle-invasive or metastatic disease. Secondary outcomes were disease recurrence, and overall and cancer-specific survival. For reproducibility, the primary outcome was interobserver variability between pathologists. Secondary outcome was intraobserver variability (repeatability) by the same pathologist. EVIDENCE SYNTHESIS: Of 3593 articles identified, 20 were included in the prognostic review; three were eligible for the reproducibility review. Increasing tumour grade in both classifications was associated with higher disease progression and recurrence rates. Progression rates in grade 1 patients were similar to those in low-grade patients; progression rates in grade 3 patients were higher than those in high-grade patients. Survival data were limited. Reproducibility of the 2004/2016 system was marginally better than that of the 1973 system. Two studies on repeatability showed conflicting results. Most studies had a moderate to high risk of bias. CONCLUSIONS: Current grading classifications in NMIBC are suboptimal. The 1973 system identifies more aggressive tumours. Intra- and interobserver variability was slightly less in the 2004/2016 classification. We could not confirm that the 2004/2016 classification outperforms the 1973 classification in prediction of recurrence and progression. PATIENT SUMMARY: This article summarises the utility of two different grading systems for non-muscle-invasive bladder cancer. Both systems predict progression and recurrence, although pathologists vary in their reporting; suggestions for further improvements are made.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Soukup V, Čapoun O, Cohen D, et al. Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review. Eur Urol. 2017. PMID: 28457661. doi:10.1016/j.eururo.2017.04.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。